None listed
Conditions
Brief summary
There is a well established physiological basis for the proposition that a potent NMDA receptor antagonist such as the widely available drug ketamine given peri-operatively may reduce the development of chronic postsurgical pain in patients undergoing major surgery, and this proposition is supported by available data pooled from small placebo controlled published studies, and a large study on N2O. The potential benefits of this in reducing the burden of chronic pain in the community are substantial. A large multicentre randomized trial is needed in patients undergoing major surgery to determine whether chronic post-surgical pain is reduced using intravenous ketamine given peri-operatively.
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
Patients undergoing elective abdominal or non-cardiac thoracic surgery under general anaesthesia involving a skin incision at least 8 cm in length and a hospital stay of at least one night postoperatively.
Exclusion criteria
Patients unable to provide informed consent Patients with poor English language comprehension Patients who are pregnant Body mass index (BMI) over 40 kg/m2 or weight over 130kg ASA grade 4 or 5. Uncontrolled hypertension (SBP over 180 mmHg) or heart failure Intracranial surgery History of haemorrhagic stroke Previous adverse reaction to ketamine Patients with a documented chronic pain syndrome identified using the mBPI Patients with epilepsy or history of convulsions Patients with a history of psychiatric problems or drug abuse or illegal activities